Constipation is a common and distressing problem for patients with advanced cancer, often leading to discomfort and reduced quality of life. Many factors contribute to constipation in these patients, including reduced mobility, inadequate fluid intake, and the use of pain-relieving opioids. Despite various treatment options available, managing constipation effectively remains challenging.

This study aims to evaluate the effectiveness of a combination of two commonly used laxatives like Polyethylene Glycol ie PEG and Bisacodyl—in relieving constipation among patients receiving palliative care. PEG helps retain water in the intestines, softening stools, while Bisacodyl stimulates bowel movements.

The study will be conducted at the Tata Memorial Hospital’s Palliative Medicine Outpatient Department in Mumbai. It is a prospective observational study, meaning researchers will monitor and analyze patients’ responses to this treatment without altering standard medical care. Patients who meet the eligibility criteria and consent to participate will receive the PEG + Bisacodyl combination, and their bowel movements and symptom relief will be assessed  after 48 hours.

The primary goal is to determine the percentage of patients who have a bowel movement within 48 hours of starting the laxative.

Secondary objectives include assessing changes in constipation severity, patient-reported side effects, and adherence to the prescribed laxative regimen.

The findings from this study will help improve constipation management in palliative care settings, ensuring better comfort and quality of life for patients with advanced cancer.